Clinical trials: Hepatitis
Acute Hepatitis C, HIV
Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
The purpose of this study is to assess the rate of sustained virological response (SVR) 12 weeks after 8-week oral treatment with grazoprevir 100mg/elbasvir 50mg (MRK-combo) in patients with acute hepatitis C genotype1 or 4.
- Trial name
- SAHIV (NCT02886624)
- Testing
- Grazoprevir/Elbasvir
- Where
- 6 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
This study will have two parts as follows: The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric…
- Trial name
- NCT02175758
- Testing
- SOF, RBV
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Severe Acute Decompensated Alcoholic Hepatitis
Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis
The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis
- Trial name
- NCT03452540
- Testing
- 1000mg DS102 (BID)
- Where
- 8 sites in United States, Georgia
- Volunteers
- 9 people
- Sponsor
- Afimmune
Hepatitis C, Chronic
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
This multi-center, observational study will evaluate the efficacy and safety of dual and triple therapies based on Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C.
- Trial name
- NCT01604291
- Where
- 21 sites in Israel
- Volunteers
- 991 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently…
- Trial name
- NCT00307489
- Testing
- tenofovir DF, emtricitabine /tenofovir DF
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
The purpose of this study is to provide anti-hepatitis C virus drugs to patients who received placebo + peginterferon alfa-2a + ribavirin in prior Bristol-Myers Squibb (BMS) studies and determine whether addition of these drugs…
- Trial name
- NCT01428063
- Testing
- Daclatasvir, Asunaprevir, Pegylated interferon alfa-2a
- Where
- 106 sites in United States, Argentina and 17 more
- Volunteers
- 276 people
- Sponsor
- Bristol-Myers Squibb
Respiratory Failure, Hepatitis C
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03625687
- Testing
- Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Hepatitis B, Chronic
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional…
- Trial name
- NCT04465916
- Testing
- EYP001a, Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
- Where
- 18 sites in Australia, Hong Kong and 2 more
- Volunteers
- 26 people
- Sponsor
- Enyo Pharma
Hepatitis A, Hepatitis B
Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult
This study will evaluate the persistence of the immune response to HAV (hepatitis A virus) antigens and HBs (hepatitis B surface) antigens in healthy adults previously vaccinated with Twinrix Adult in the primary study, HAB-032…
- Trial name
- NCT01037114
- Testing
- Blood sampling, Engerix-B, Havrix
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis D
Lonafarnib for Chronic Hepatitis D
Background: Chronic hepatitis D is a severe disease of the liver caused by infection with the hepatitis D virus. The hepatitis D virus can only infect a person who also has hepatitis B; therefore, people with delta hepatitis have…
- Trial name
- NCT01495585
- Testing
- Lonafarnib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Chronic
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent…
- Trial name
- NCT00516321
- Testing
- eltrombopag
- Where
- 191 sites in United States, Australia and 23 more
- Volunteers
- 687 people
- Sponsor
- GlaxoSmithKline
Hepatitis C
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic…
- Trial name
- PILLAR (NCT00882908)
- Testing
- TMC435, Ribavirin (R), PegIFNα-2a (P)
- Where
- 71 sites in United States, Australia and 11 more
- Volunteers
- 386 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis B Virus
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
The goal of this study is to evaluate two sets of interventions to increase acceptance of hepatitis B virus (HBV) vaccination in patients attending sexually transmitted disease (STD) clinics.
- Trial name
- NCT00739752
- Testing
- Non-Framed-Offered, Non-Framed-Recommended, Gain-Framed-Offered
- Where
- 2 sites in United States
- Volunteers
- 1,747 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV
Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women
This study will inform international medical guidelines as to whether the Levonorgestrel intrauterine device (LNG IUD), a highly effective long-acting reversible contraceptive method, is safe and acceptable as compared to the…
- Trial name
- NCT01721798
- Testing
- Mirena levonorgestrel IUD, Copper T-380a IUD
- Where
- South Africa
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- FHI 360
Hepatitis C
Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment
The purpose of this study is to test the potential antiviral efficacy of triple-combination therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype 3 who previously failed Peginterferon α +…
- Trial name
- LeeG3 (NCT01585584)
- Testing
- Boceprevir
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of Calgary
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Hepatitis C
Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
Qualitative pilot study of patients' views of their experience with antiviral treatment for hepatitis C.
- Trial name
- NCT00674492
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- US Department of Veterans Affairs
Acute Alcoholic Hepatitis
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91.
- Trial name
- NCT02612428
- Testing
- ELAD System, Standard of Care (Control)
- Where
- 44 sites in United States, Austria and 4 more
- Volunteers
- 151 people
- Sponsor
- Vital Therapies, Inc.
Hepatitis C, Chronic, Genotype 1
Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC), and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to standard clinical practice, on the…
- Conditions
- Hepatitis C, Chronic, Genotype 1, HCV-1
- Trial name
- VIDA (NCT00863109)
- Testing
- Peginterferon alfa-2b (PEG), Ribavirin (RBV)
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Polio
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP~T…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00362336
- Testing
- DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric
- Where
- 2 sites in South Africa
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.